NECTIN4-CD137 BsAb therapy(Novarock Biotherapeutics)

N/A

Report date: 2023/11/30 16:56:39

Base Information

Drug NameNECTIN4-CD137 BsAb therapy(Novarock Biotherapeutics)
Drug Alias NameNECTIN4-CD137
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Tumor necrosis factor receptor superfamily member 9Anti-NECTIN4
TargetsTumor necrosis factor receptor superfamily member 9Nectin-4
Therapy Area/IndicationsUrinary Bladder NeoplasmsEsophageal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNovarock Biotherapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNovarock Biotherapeutics Ltd
Inactive CompaniesN/A
Active IndicationsUrinary Bladder NeoplasmsEsophageal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A